Drug Landscape ›
ESCITALOPRAM ›
Regulatory · United States
Marketing authorisation
FDA
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
Window: 20 April 2025 – 20 April 2026
Total reports: 37,852
Most-reported reactions
Drug Ineffective — 4,826 reports (12.75%) Fatigue — 4,630 reports (12.23%) Nausea — 4,453 reports (11.76%) Off Label Use — 3,823 reports (10.1%) Headache — 3,768 reports (9.95%) Diarrhoea — 3,716 reports (9.82%) Drug Interaction — 3,228 reports (8.53%) Dizziness — 3,198 reports (8.45%) Fall — 3,111 reports (8.22%) Anxiety — 3,099 reports (8.19%)
Source database →
ESCITALOPRAM in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is ESCITALOPRAM approved in United States?
Yes. FDA has authorised it.
Who is the marketing authorisation holder for ESCITALOPRAM in United States?
Marketing authorisation holder not available in our data.